Neurological Disorders
WASHINGTON - Allergan Inc., the maker of wrinkle-smoothing Botox, says it will pay $600 million to settle a five-year-long federal investigation into its marketing of the top-selling, botulin-based drug.
WASHINGTON - Federal health regulators are warning doctors and patients that an anti-seizure drug from GlaxoSmithKline PLC can cause rare inflammation of the brain and spinal cord.
WASHINGTON - Federal health advisers have ruled that GlaxoSmithKline's epilepsy drug Potiga effectively controls seizures.
WASHINGTON - Doctors can't tell if Leif Utoft Bollesen's mild memory loss will remain an annoyance or worsen, but experimental checks of the Minnesota man's aging brain may offer clues.
More News
- FDA approves larger dose of Pfizer's Aricept
- Alzheimer's advances show need for better drugs
- A look at recent failures in Pfizer drug research
- Latest Pfizer drug failure shows worrisome trend
- Drug companies share data to speed brain research
- Watson says court affirms ADHD drug patent ruling
- Shire sues Teva over generic ADHD drug Intuniv
- President LBJ's youngest daughter hospitalized
- Experts: Lithium doesn't slow Lou Gehrig's disease
- Current drugs for symptoms of Alzheimer's disease
- Summary Box: Alzheimer's drug fails in late test
- Medivation tumbles on Dimebon trial failure
- Pfizer Alzheimer's disease drug fails in study
- Novartis gets US approval for meningitis vaccine
- Irish drugmaker Elan records Q4 loss, sees rebound
- Pfizer pares, refocuses research after Wyeth buy
- Teva hails milder restrictions on Parkinson's drug
- Sangamo says early data from ALS study is positive
- CytRx: FDA lifts 2-year hold on arimoclomol tests
- Vaccines on horizon for AIDS, Alzheimer's, herpes
- Business Highlights
- Going high-tech to track Alzheimer's patients
